Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 40 of 46 for:    SIR-Spheres

REgistry of Selective Internal Radiation Therapy in TaiwaN (RESIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03292991
Recruitment Status : Recruiting
First Posted : September 26, 2017
Last Update Posted : September 26, 2017
Sponsor:
Collaborators:
Kaohsiung Veterans General Hospital.
National Taiwan University Hospital
National Cheng-Kung University Hospital
China Medical University Hospital
Chang Gung Memorial Hospital
Mackay Memorial Hospital
Information provided by (Responsible Party):
vghtpe user, Taipei Veterans General Hospital, Taiwan

Brief Summary:
All study objectives will be assessed in HCC patients or colorectal cancer patients with secondary metastases in the liver, respectively.

Condition or disease
Hepatocellular Carcinoma

Detailed Description:

All study objectives will be assessed in HCC patients or colorectal cancer patients with secondary metastases in the liver, respectively.

  1. Primary objective:

    • To observe the safety of SIR-Spheres® microspheres therapy (SIRT)by,

      • Adverse events and serious adverse events (non-specific and radiation specific)
      • Changes in liver function parameters
    • To observe the efficacy of SIR-Spheres® microspheres therapy by, assessing the best overall response rate after SIRT
  2. Secondary objectives:

    • To observe the efficacy of SIRT by,

      • Overall survival (OS)
      • Overall/objective response rate (ORR)
      • Time-to-progression
      • Time-to-liver progression
      • Progression-free survival
    • To observe the changes in clinical presentation after SIRT by,

      • ECOG score
      • Child-Pugh score
      • Percentage of subjects with down-staging or down-sizing of treated lesion to resection, transplantation, or radiofrequency ablation (RFA)
    • To observe the practice pattern of SIRT by,

      • Median dosage (GBq)
      • Number of SIRT sessions received by subjects
  3. Exploratory objectives:

    • To explore prognostic factors for disease progression after SIRT by comparing the following parameters:

      • Number of tumors in subjects prior to SIRT
      • Median tumor size in subjects prior to SIRT
      • Location of tumor in subjects treated with SIRT (hepatic segment or lobe)
      • Number of prior TACE treatment in subjects
      • Antiviral therapy subjects HCC

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 2 Years
Official Title: REgistry of Selective Internal Radiation Therapy in TaiwaN (RESIN)
Actual Study Start Date : June 9, 2015
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019



Primary Outcome Measures :
  1. Safety as per CTCAE 4.03, incidence of AEs and baseline change in liver function paired t-test or Wilcoxon signed rank test. [ Time Frame: 6 months ]
    Toxicity will be accessed according to CTCAE v4.03. The incidence of adverse events will be summarized and the change in baseline liver function will be assessed by paired t-test or Wilcoxon signed rank test.


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 1 year ]
    Overall survival (OS) is determined for all enrolled subjects from Day 0 to the date of death or last contact.

  2. Overall Response Rate per RECIST 1.1 and mRECIST [ Time Frame: 1 year ]

    Liver tumor assessments for CRC will be evaluated by RECIST v1.1; and tumor assessments for HCC will be evaluated by mRECIST.

    - Objective Response Rate is defined as the proportion of subjects with tumor size reduction (i.e. the combined proportion of subjects with CR and PR) from Day 0 until documented tumor progression.


  3. Time-to-progression per RECIST 1.1 and mRECIST [ Time Frame: 1 year ]
    The time-to-progression (TTP) is calculated by the time from Day 0 to the date of disease progression (PD).

  4. Time-to-liver progression per RECIST 1.1 and mRECIST [ Time Frame: 1 year ]
    The time-to-liver progression is calculated by the time from Day 0 to the date of tumor progression (PD) in intrahepatic lesions.

  5. Progression-free survival [ Time Frame: 1 year ]
    Progression free survival (PFS) is determined for all enrolled patients from Day 0 until tumor progression or patient death.

  6. Liver resection rate [ Time Frame: 1 year ]
    Patients will be assessed for suitability for liver resection every study visit during the study period.

  7. Liver transplantation rate [ Time Frame: 1 year ]
    Patients will be assessed for suitability for liver transplantation every study visit during the study period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
HCC patients or colorectal cancer patients with secondary metastases in the liver.
Criteria

Inclusion Criteria, Patients who meet all inclusion criteria will be included:

  • Males or non-pregnant females, at least 18 years of age (inclusive).
  • Patients with clinically confirmed hepatocellular carcinoma (HCC) OR adenocarcinoma of colon/rectum with liver metastasis.
  • Patients with liver dominant disease.
  • Tumor burden ≤ 70% of total liver volume.
  • HCC patients with child-Pugh Score class A or B.
  • HCC patients with Barcelona-Clinic Liver Cancer (BCLC) stage A-C.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
  • Patients who are unsuitable for resection or immediate liver transplantation or who cannot be optimally treated with local ablation.
  • Patients who have provided written informed consent.

Exclusion Criteria, Patients who meet any exclusion criteria will be excluded:

  • Patients known to be hypersensitive to any component of study product.
  • Female patients who are pregnant or lactating. Women of child bearing potential who disagree to practice medically recognized birth control methods throughout the study (from Screening to approximately 6 months post SIRT). Medically recognized birth control methods include hormonal contraceptives, intrauterine device/IUD, barrier device, or abstinence. With the exception of women who had been surgically sterilized (defined as having undergone hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation alone is not considered sufficient), or one year post-menopausal.

Withdrawal criteria:

  • Patients consent withdrawal.
  • Lost to follow-up for 2 consecutive visits.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03292991


Contacts
Layout table for location contacts
Contact: Rheun-Chuan Lee, M.D. +886-2-28712121 ext 3069 vghtpeyttrium90@gmail.com

Locations
Layout table for location information
Taiwan
Taipei Veterans General Hospital Recruiting
Taipei, Taiwan, 11217
Contact: Rheun-Chuan Lee, M.D.    +886-2-28712121 ext 3069    vghtpeyttrium90@gmail.com   
Sponsors and Collaborators
Taipei Veterans General Hospital, Taiwan
Kaohsiung Veterans General Hospital.
National Taiwan University Hospital
National Cheng-Kung University Hospital
China Medical University Hospital
Chang Gung Memorial Hospital
Mackay Memorial Hospital
Investigators
Layout table for investigator information
Principal Investigator: Rheun-Chuan Lee, M.D. Taipei Veterans General Hospital, Taiwan

Additional Information:

Layout table for additonal information
Responsible Party: vghtpe user, Principal Investigator, Dr. Rheun-Chuan Lee, Taipei Veterans General Hospital, Taiwan
ClinicalTrials.gov Identifier: NCT03292991     History of Changes
Other Study ID Numbers: QCR14021
First Posted: September 26, 2017    Key Record Dates
Last Update Posted: September 26, 2017
Last Verified: September 2017
Keywords provided by vghtpe user, Taipei Veterans General Hospital, Taiwan:
Hepatocellular Carcinoma
SIR Spheres
SIRT
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases